Cumberland Pharmaceuticals CPIX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Acetadote | $51.98K-65.7% | $66.67K+65.8% | $96.6K+352% | $193.55K+346% | $151.65K+89.1% | |
| Caldolor | $965.56K-26.1% | $896.71K-34.7% | $867.01K-31.8% | $1.59M+88.1% | $1.31M-11.1% | |
| Kristalose | $981.48K-71.8% | $3.12M-28.7% | $1.18M-67.5% | $2.75M-33.0% | $3.48M+9.0% | |
| Other revenue | $168.85K-94.6% | $184.62K-14.9% | $306.51K-50.9% | $492.39K+130% | $3.14M+1,041% | |
| Sancuso | $2.93M+29.8% | $3.29M+38.2% | $3.24M+24.3% | $3.12M+42.5% | $2.26M+23.4% | |
| Talicia | $1.92M— | —— | —— | —— | $0— | |
| Vibativ | $2.12M-29.4% | $2.81M+35.4% | $2.6M+153% | $2.7M+10.1% | $3M+86.9% | |
| Revenues, including adjustments by Product | ||||||
| Omeclamox-Pak | $1+100% | —— | -$3.13K-17,272% | -$752+20.1% | -$5.39K-162% | |
| RediTrex | -$489-40.9% | —— | $4.43K-88.0% | $3.24K+381% | -$347-101% | |
| Vaprisol | $517+186% | —— | $600+100% | -$14.62K-825% | -$600+62.8% | |
| Non-current inventories by Product | ||||||
| Acetadote | $23.14K-14.6% | $24.15K+1.0% | $69.62K+121% | $0-100% | $27.11K+8.2% | |
| Caldolor | $95.14K-46.6% | $112.76K+45.7% | $118.22K+118% | $162.89K+65.8% | $178.13K+234% | |
| Ifetroban | $40.88K-72.8% | $40.88K-75.5% | $65.27K-67.9% | $65.27K-67.9% | $150.4K— | |
| Kristalose | $2.26M-6.5% | $2.26M-15.4% | $2.36M-17.1% | $2.58M-9.3% | $2.42M-24.6% | |
| Sancuso | $615.87K+60.0% | $656.67K+43.2% | $285.15K-54.5% | $326.12K-39.2% | $384.91K-33.5% | |
| Vaprisol | $1.17M-0.1% | $1.17M-0.1% | $1.17M0.0% | $1.17M-0.1% | $1.17M— | |
| Vibativ | $5.56M+3.8% | $4.88M-21.0% | $4.71M-24.3% | $4.98M-26.5% | $5.36M-19.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Cumberland Pharmaceuticals break its business down?
- Cumberland Pharmaceuticals (CPIX) reports revenue by product across 7 parts — Acetadote, Caldolor, Kristalose, Other revenue and Sancuso. Each is extracted from the segment footnotes and tracked over time.
- Where does Cumberland Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Cumberland Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
